Business

Investigators Weigh Differences in Biosimilar Quality Reporting

January 23rd 2021

By Deana Ferreri, PhD

Consistency of reporting quality attributes for biosimilars may differ, complicating the job of getting a full picture of biosimilarity.

Prestige Biopharma Plots Biosimilar Growth Strategy

January 20th 2021

By Tony Hagen

Biosimilars will be the cornerstone for a leap into biologics development and commercialization, according to the CEO of Prestige Biopharma. Also, Innovent Biologics reaches a marketing agreement.

Poll: Which of the following is true about insulin products and the BPCIA?

January 20th 2021

Many patient advocates hope that expansion of the Biologics Price Competition and Innovation Act (BPCIA) will bring further competition to the insulin market—and lower prices.

IGBA, Celltrion, Others Mark Biosimilar Advances

January 17th 2021

By Tony Hagen

The Center for Biosimilars® reports on developments at the International Generic and Biosimilar Medicines Association (IGBA), Celltrion, Innovent Biologics, and Kamada.

Infliximab Biosimilar Switching Study Yields Evidence of Safety, Efficacy

January 14th 2021

By Deana Ferreri, PhD

A need for clinical evidence on the efficacy and safety of infliximab switching led the authors to pursue this investigation.

Study: Machine Learning Could Optimize Biosimilar Therapy

January 12th 2021

By Deana Ferreri, PhD

Authors of a new study conclude that artificial intelligence could improve the selection of biosimilars for therapy.

Data From HERITAGE Confirm PK Biosimilarity for Ogivri

January 9th 2021

By Tony Hagen

Pharmacokinetic (PK) parameters matched up with those of reference trastuzumab in an extended analysis of data from the HERITAGE trial.

Economists Probe Cost-Effectiveness of Biosimilars

January 7th 2021

By Tony Hagen

Authors of a review found that biosimilar uptake and market share are not in themselves sufficient to establish whether these agents will lead to savings.

Investigators Chart ABP 980 Biosimilar Uptake in European Clinics

January 4th 2021

By Tony Hagen

Among patients treated for metastatic breast cancer, 40% switched to ABP 980.

Alvotech Breaks Ground for Biosimilar Development Facility

January 3rd 2021

By Tony Hagen

An expansion of its Reykjavik, Iceland, headquarters operation will speed the company on its way to launching its first biosimilars, officials said.